Web1 day ago · CNM-Au8 found to delay clinical worsening in ALS HEALEY trial. ... Phase 2a ALS clinical trial was able to efficiently inform us about the biological efficacy and [central nervous system] drug delivery of AIT-101 in C9ORF72 ALS individuals, using a relatively small sample size, short placebo exposure duration and short trial duration overall ... WebApr 10, 2024 · The HEALEY ALS Platform Trial is a large-scale collaborative effort made possible by contributions from patients and families, clinical trial sites, industry partners …

Clene Nanomedicine Announces Achievement of 50% Enrollment

WebJan 27, 2024 · by Marta Figueiredo, PhD January 27, 2024 The U.S. Food and Drug Administration (FDA) has authorized the evaluation of the first three candidate therapies for amyotrophic lateral sclerosis (ALS) in the HEALEY ALS Platform Trial. WebThe HEALEY ALS Platform Trial (first-ever ALS platform trial) designed to decrease the amount of time it will take to find successful therapies, improve active study medication to placebo ratio, and increase access for participants. One of the innovative features of the Platform Trial is that enrollment will continue perpetually as more ... css silver color

AIT-101 clears toxic protein clumps in early clinical trial for ALS ...

WebFeb 21, 2024 · The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS. WebMar 29, 2024 · The Healey ALS Platform Trial. Inception—The primary aim of the Healey ALS Platform Trial is to compare the efficacy of novel/emerging therapies against a shared placebo group for participants with sporadic or familial ALS. Dr. Cudkowicz submitted the initial investigational new drug application to the FDA, so she serves as the study sponsor. WebApr 15, 2024 · Prilenia Therapeutics, a small biotechnology company targeting neurodegenerative diseases, recently completed a Phase 2 trial of their drug Pridopidine … css simhei